切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2014, Vol. 02 ›› Issue (03) : 158 -161. doi: 10.3877/cma.j.issn.2095-5820.2014.03.006

综述

产新德里金属β-内酰胺酶-1耐药菌研究进展
楼丹萍1, 余方友2,()   
  1. 1.322100 浙江省东阳市人民医院呼吸科
    2.322100 温州医科大学附属第一医院检验科
  • 收稿日期:2014-08-09 出版日期:2014-08-28
  • 通信作者: 余方友

Advance on drug-resistant bacteria producing New Delhi metallo-β-lactamases-1

Danping Lou1, Fangyou Yu2,()   

  1. 1.Department of Respiratory Medicine,Dongyang People’s Hospital, Dongyang, Zhejiang 322100, China
    2.Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 32500, China
  • Received:2014-08-09 Published:2014-08-28
  • Corresponding author: Fangyou Yu
引用本文:

楼丹萍, 余方友. 产新德里金属β-内酰胺酶-1耐药菌研究进展[J/OL]. 中华临床实验室管理电子杂志, 2014, 02(03): 158-161.

Danping Lou, Fangyou Yu. Advance on drug-resistant bacteria producing New Delhi metallo-β-lactamases-1[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2014, 02(03): 158-161.

产新德里金属β-内酰胺酶-1(New Delhi metallo-β-lactamases-1,NDM-1)耐药菌对现有的大多数抗菌药物包括β-内酰胺类、碳青霉烯类、氨基糖苷类、大环内酯类和喹诺酮类等具有广泛的耐药性,仅对替加环素和多黏菌素敏感,给临床治疗带来很大困难。在此,对产NDM-1耐药菌的流行病学、生物学特点、耐药机制、检测和临床防治予以阐述。

Drug-resistant bacteria producing New Delhi metallo-β-lactamase-1 (NDM-1) is a new challenge to the clinical treatment. It resistants to β-lactams including carbapenems, aminoglycosides, macrolides and quinolones and other antimicrobial agents. Only tigecycline and polymyxin maintained activities against the bacteria with NDM-1. This article introduced the molecular characteristics, mechanism of drug resistance, detecting methods,and prophylaxis and treatment of bacteria with NDM-1.

1
Nordmann P, Naas T, Poirel L,et al. Global spread of Carbapenemase-producing Enterobacteriaceae[J]. Emerg Infect Dis,2011, 17(10): 1791-1798.
2
Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study[J]. Lancet Infect Dis,2010, 10(9): 597-602.
3
Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India[J]. Antimicrobial Agents Chemother, 2009, 53(12): 5046-5054.
4
Deshpande P, Rodrigues C, Shetty A, et al. New Delhi metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised[J]. J Assoc Physicians India, 2010, 58:147-149.
5
Johnson AP, Woodford N. Global spread of antibiotic resistance:the example of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance[J]. J Med Microbiol, 2013, 62(Pt 4): 499-513.
6
Chen Y, Zhou Z, Jiang Y, et al. Emergence of NDM-1-producing Acinetobacter baumannii in China[J]. J Antimicrobial Chemother,2011, 66(6): 1255-1259.
7
Dai W, Sun S, Yang P, et al. Characterization of carbapenemases,extended spectrum beta-lactamases and molecular epidemiology of carbapenem-non-susceptible Enterobacter cloacae in a Chinese hospital in Chongqing[J]. Infect Genet Evol, 2013, 14: 1-7.
8
Hu L, Zhong Q, Tu J, et al. Emergence of blaNDM-1 among Klebsiella pneumoniae ST15 and novel ST1031 clinical isolates in China[J].Diagn Microbiol Infect Dis, 2013, 75(4): 373-376.
9
Wang X, Xu X, Li Z, et al. An outbreak of a nosocomial NDM-1-producing Klebsiella pneumoniae ST147 at a teaching hospital in mainland China[J]. Microb Drug Resist, 2014, 20(2):144-9.
10
Zhang X, Lou D, Xu Y, et al. First identification of coexistence of blaNDM-1 and blaCMY-42 among Escherichia coli ST167 clinical isolates[J]. BMC Microbiol, 2013, 13: 282.
11
邹明祥,邬靖敏,李军,等. 产NDM-1肺炎克雷伯菌中国分离株的初步研究[J]. 中国当代儿科杂志, 2012, 14(8): 616-621.
12
Nordmann P, Poirel L, Walsh TR, et al. The emerging NDM carbapenemases. Trends Microbiol, 2011, 19(12): 588-595.
13
Walsh TR, Weeks J, Livermore DM, et al. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study[J]. Lancet Infect Dis, 2011, 11(5): 355-362.
14
Nordmann P, Poirel L, Toleman MA, et al. Does broad-spectrum betalactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria[J]? J Antimicrobial Chemother, 2011, 66(4): 689-692.
15
Owens RC Jr, Johnson JR, Stogsdill P, et al. Community transmission in the United States of a CTX-M-15-producing sequence type ST131 Escherichia coli strain resulting in death[J]. J Clin Microbiol, 2011,49(9): 3406-3408.
16
Kaase M, Nordmann P, Wichelhaus TA, et al. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt[J]. J Antimicrobial Chemother,2011, 66(6): 1260-1262.
17
Chan HL, Poon LM, Chan SG, et al. The perils of medical tourism:NDM-1-positive Escherichia coli causing febrile neutropenia in a medical tourist[J]. Singapore Med J, 2011, 52(4): 299-302.
18
Dortet L, Nordmann P, Poirel L. Association of the emerging carbapenemase NDM-1 with a bleomycin resistance protein in Enterobacteriaceae and Acinetobacter baumannii[J]. Antimicrobial Agents Chemother, 2012, 56(4): 1693-1697.
19
Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med, 2012, 18(5):263-272.
20
Bercot B, Poirel L, Dortet L, et al. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae[J]. J Antimicrobial Chemother, 2011, 66(10): 2295-2297.
21
Nordmann P, Poirel L, Carrer A, et al. How to detect NDM-1 producers[J]. J Clin Microbiol, 2011, 49(2): 718-721.
22
Pillai DR, McGeer A, Low DE. New Delhi metallo-beta-lactamase-1 in Enterobacteriaceae: emerging resistance[J]. CMAJ, 2011, 183(1): 59-64.
23
Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae[J]. Antimicrobial Agents Chemother,2011, 55(1): 390-394.
[1] 王雪菲, 海琳悦, 李立方, 肖春花. Luminal A型乳腺癌的内分泌治疗与化疗[J/OL]. 中华乳腺病杂志(电子版), 2023, 17(05): 294-300.
[2] 涂家金, 廖武强, 刘金晶, 涂志鹏, 毛远桂. 严重烧伤患者鲍曼不动杆菌血流感染的危险因素及预后分析[J/OL]. 中华损伤与修复杂志(电子版), 2023, 18(06): 491-497.
[3] 袁柳凤, 徐文绮, 朱小宇, 王慧珠, 伦文辉. 283株淋球菌对七种常见抗菌药物的耐药性分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 108-112.
[4] 韦涌涛, 王松霞, 苏爱美, 王东平. 耐碳青霉烯类铜绿假单胞菌耐药性及联合药敏试验研究[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(01): 43-48.
[5] 张海金, 王增国, 蔡慧君, 赵炳彤. 2020至2022年西安市儿童医院新生儿细菌感染分布及耐药监测分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2023, 17(04): 222-229.
[6] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[7] 巨春蓉, 门同义, 薛武军. 实体器官移植后难治性/耐药性巨细胞病毒感染诊疗进展[J/OL]. 中华移植杂志(电子版), 2024, 18(02): 86-92.
[8] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[9] 邢嘉翌, 龚佳晟, 祝佳佳, 陆群. 肺癌化疗患者继发肺部感染的病原菌耐药性及炎症因子变化分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 714-718.
[10] 王蕊, 林先萍, 李盼盼. 铜绿假单胞菌感染肺炎菌血症危险因素及耐药性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 478-480.
[11] 蔡小芳, 高慧, 葛军, 邢慧芸, 庄小燕, 李小丁. 多重耐药性肺结核治疗依从性预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(01): 51-56.
[12] 刘法永, 胡萍, 戴丽. 获得性肺炎患者血流感染病原菌分布及耐药性分析[J/OL]. 中华肺部疾病杂志(电子版), 2022, 15(05): 666-669.
[13] 黎金秋, 韦晓芳, 王成玉. 腹膜透析相关性腹膜炎细菌谱变迁及药敏分析[J/OL]. 中华肾病研究电子杂志, 2022, 11(05): 264-269.
[14] 林舒楠, 党文强, 钟天, 梁斯欣, 张磊, 唐晓华, 袁文常. 2017—2021年广东地区基层医疗机构金黄色葡萄球菌临床分离株耐药谱分析[J/OL]. 中华临床实验室管理电子杂志, 2023, 11(03): 139-144.
[15] 刁福强, 罗欣, 古春明, 唐玲玲. 广州某医院儿童社区获得性肺炎病原菌分布及耐药性分析[J/OL]. 中华临床实验室管理电子杂志, 2023, 11(01): 38-44.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?